Key Highlights: Implications: Relopduo gives BMS a next‑generation immunotherapy in India’s melanoma market, combining PD‑1 and LAG‑3 blockade to offer materially better pro...
Key Highlights: Implications: Tecentriq’s 7‑minute under‑the‑skin version should help Roche deepen its lung cancer business in India by easing pressure on overcrowded infusion centers...
